Previous Close | 0.3000 |
Open | 0.3000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 10.00 |
Expire Date | 2024-07-19 |
Day's Range | 0.3000 - 0.3000 |
Contract Range | N/A |
Volume | |
Open Interest | 77 |
CAMBRIDGE, Mass., June 13, 2024--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a webcast event with medical experts to discuss the unmet need in higher-risk myelodysplastic syndrome (HR-MDS) and the opportunity for tamibarotene to transform the care of newly diagnosed patients with RARA gene overexpression. The event will take place on Tuesday
Explore key updates on clinical trials, financial shifts, and strategic insights from Syros Pharmaceuticals' Q1 2024 earnings call.
Q1 2024 Syros Pharmaceuticals Inc Earnings Call